Could Some Patients Stop Taking Their CML Medications?

If a CML patient is doing well on one of the TKI (Tyrosine Kinase Inhibitor) drugs, could they someday stop their treatment? Dr. Raoul Tibes from the Mayo Clinic explores this concept and shares his opinion.
Experts & Guests
|
Raoul Tibes, M.D., Ph.D.
Senior Associate Consultant, Mayo Clinic, Mayo Clinic
Dr. Tibes is a physician-scientist who sees and treats patients with hematological malignancies as well as heads laboratory research efforts in leukemia research. Further, he is actively conducting early phase (Phase 1/2) clinical trials with novel molecular therapies/agents.
more >
|
|
|


















































